Business Context and Reporting Period
MiMedx Group, Inc. (MDXG) filed a Form 8-K on January 10, 2022, to disclose unaudited preliminary financial results for the full year ended December 31, 2021, and to announce upcoming investor communications.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release and presentation (Exhibits 99.1 and 99.2) containing these unaudited preliminary results for 2021, but the figures are not included in the body of this Current Report.
Material Changes
No specific material changes versus the prior comparable period are detailed in this filing text. The document serves as a notification that such results have been issued and will be presented to investors.
Guidance, Outlook, and Management Commentary
- Investor Events: CEO Timothy R. Wright and CFO Peter M. Carlson are scheduled to meet with investors starting January 10, 2022, and present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022.
- 2022 Expectations: The company issued a press release on January 10, 2022, announcing its expectations for financial and other results for the year ending December 31, 2022. Specific guidance figures are not listed in this text.
- Exhibits: Detailed information is contained in the Slide Presentation (Exhibit 99.1) and Press Release (Exhibit 99.2), which are incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.2 (Press Release) for specific 2021 preliminary financial results and 2022 guidance figures.
- Access the Slide Presentation (Exhibit 99.1) for detailed management commentary and strategic outlook.
- Verify the live webcast or recording of the J.P. Morgan Healthcare Conference presentation scheduled for January 12, 2022.
- Note that the information in the exhibits is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.